{"release_id":19,"data":{"id":89915,"release_id":19,"source_id":"sgkb.data.biomedical-pharma-anchors","kind":"dataset","fingerprint":"963847963285ce6b2e01a9659e8d21e8f97488f9dd7752a948abadffe4bf36b3","title_en":"Biomedical and Pharma Anchors","title_zh":"\u751f\u7269\u533b\u836f\u4e0e\u5236\u836f\u4e1a\u652f\u67f1","domain":"data","status":"verified","assurance":null,"subtype":null,"lat":null,"lon":null,"date":"2026-08-09","payload":{"bundle_sha256":"45bf7e4a6e04877a9385caa9d5613e31f964959fced55c1117ce10170e4f73ce","checks":{"citations":"passed","translation":"passed"},"data":{"aliases":["BMS manufacturing","Tuas Biomedical Park","Biopolis"],"aliases_i18n":[],"canonical_format":"markdown","classification_confidence":"high","classification_source":"curated","document_id":"sgkb.data.biomedical-pharma-anchors","document_sha256":"8f6acb12a339ee33ae4721eb4494198ace56c8d1992f128224d55dad55cf2830","document_type":"dataset","domain":"data","entities":["sg.agency.edb","sg.agency.astar","sg.agency.hsa"],"facets":["business","current","institution","policy","statistics"],"geographic_scope":["national"],"grain":"one dated BMS GDP\/plant\/VA or campus investment anchor","id":"sgkb.data.biomedical-pharma-anchors","jurisdiction":"SG","language":"en","last_verified":"2026-08-09","path":"data\/biomedical-pharma-anchors.md","related":["biomedical-and-pharma","astar-and-public-research","doing-business"],"sources":[{"accessed":"2026-08-09","publisher":"Economic Development Board","tier":1,"title":"EDB \u2014 Singapore's rise as a biomedical sciences powerhouse","url":"https:\/\/www.edb.gov.sg\/en\/business-insights\/insights\/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html"},{"accessed":"2026-08-09","publisher":"Economic Development Board","tier":1,"title":"EDB \u2014 Monthly Manufacturing Performance","url":"https:\/\/www.edb.gov.sg\/en\/about-edb\/media-releases-publications\/monthly-manufacturing-performance.html"},{"accessed":"2026-08-14","published":"2026-05-26","publisher":"Economic Development Board","tier":1,"title":"EDB \u2014 Monthly Manufacturing Performance April 2026 infographic","url":"https:\/\/www.edb.gov.sg\/content\/dam\/edb-en\/about-edb\/media-releases\/manufacturing-statistics\/Monthly_Manufacturing_Activities\/Monthly%20Manufacturing%20Performance%20April%202026.pdf"},{"accessed":"2026-08-09","publisher":"Ministry of Trade and Industry","tier":1,"title":"MTI \u2014 Written reply on biomedical sector resilience","url":"https:\/\/www.mti.gov.sg\/newsroom\/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers\/"}],"status":"verified","summary":"Dated Singapore biomedical manufacturing scale, GDP contribution, plant counts, and Biopolis\/Tuas anchors \u2014 distinct from clinical healthcare financing.","tags":["manufacturing","statistics","policy","investment"],"temporal_scope":"current","title":"Biomedical and Pharma Anchors","topics":["sgtopic.business.biomedical-pharma"],"update_cadence":"after EDB manufacturing stats or BMS investment announcements","volatility":"fast"},"date":"2026-08-09","domain":"data","evidence_paths":["source\/data\/biomedical-pharma-anchors.md","artefacts\/retrieval-chunks.jsonl","artefacts\/document-classification.jsonl"],"expected_version":0,"input_hash":"a05e091888ab2000be4ba2d89210bb37ac0dbb5b1fa81a5eafd01f4126e2b27e","kind":"dataset","lineage":[{"chunk_id":"sgkb.data.biomedical-pharma-anchors#overview","citation_urls":[],"content_sha256":"2c0fc4bea4d6b1171373c0ab5b3915941074914ca67a4760c890f6707a517311","document_id":"sgkb.data.biomedical-pharma-anchors","document_sha256":"8f6acb12a339ee33ae4721eb4494198ace56c8d1992f128224d55dad55cf2830","section_sources":[]},{"chunk_id":"sgkb.data.biomedical-pharma-anchors#scale-and-gdp-contribution","citation_urls":["https:\/\/www.edb.gov.sg\/en\/business-insights\/insights\/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html"],"content_sha256":"522e770646d26191808df0c59c9896f27d70093c5c8b8df36a40139a5706fdef","document_id":"sgkb.data.biomedical-pharma-anchors","document_sha256":"8f6acb12a339ee33ae4721eb4494198ace56c8d1992f128224d55dad55cf2830","section_sources":[{"accessed":"2026-08-09","publisher":"Economic Development Board","tier":1,"title":"EDB \u2014 Singapore's rise as a biomedical sciences powerhouse","url":"https:\/\/www.edb.gov.sg\/en\/business-insights\/insights\/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html"}]},{"chunk_id":"sgkb.data.biomedical-pharma-anchors#manufacturing-cluster-share-april-2026","citation_urls":["https:\/\/www.edb.gov.sg\/en\/about-edb\/media-releases-publications\/monthly-manufacturing-performance.html","https:\/\/www.edb.gov.sg\/content\/dam\/edb-en\/about-edb\/media-releases\/manufacturing-statistics\/Monthly_Manufacturing_Activities\/Monthly%20Manufacturing%20Performance%20April%202026.pdf"],"content_sha256":"d687f692d57196fd8927e21b27861fd23b432cf4ddefc2a6257cd333e720ce64","document_id":"sgkb.data.biomedical-pharma-anchors","document_sha256":"8f6acb12a339ee33ae4721eb4494198ace56c8d1992f128224d55dad55cf2830","section_sources":[{"accessed":"2026-08-09","publisher":"Economic Development Board","tier":1,"title":"EDB \u2014 Monthly Manufacturing Performance","url":"https:\/\/www.edb.gov.sg\/en\/about-edb\/media-releases-publications\/monthly-manufacturing-performance.html"},{"accessed":"2026-08-14","published":"2026-05-26","publisher":"Economic Development Board","tier":1,"title":"EDB \u2014 Monthly Manufacturing Performance April 2026 infographic","url":"https:\/\/www.edb.gov.sg\/content\/dam\/edb-en\/about-edb\/media-releases\/manufacturing-statistics\/Monthly_Manufacturing_Activities\/Monthly%20Manufacturing%20Performance%20April%202026.pdf"}]},{"chunk_id":"sgkb.data.biomedical-pharma-anchors#investment-and-campuses","citation_urls":["https:\/\/www.mti.gov.sg\/newsroom\/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers\/"],"content_sha256":"18d3d4f61ce91964896fe75d1ca273fef314986bf808fb656ffed862f04f06ac","document_id":"sgkb.data.biomedical-pharma-anchors","document_sha256":"8f6acb12a339ee33ae4721eb4494198ace56c8d1992f128224d55dad55cf2830","section_sources":[{"accessed":"2026-08-09","publisher":"Ministry of Trade and Industry","tier":1,"title":"MTI \u2014 Written reply on biomedical sector resilience","url":"https:\/\/www.mti.gov.sg\/newsroom\/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers\/"}]}],"links":[{"relation":"related","target_id":"sgkb.business-industry.biomedical-and-pharma"},{"relation":"related","target_id":"sgkb.science-research.astar-and-public-research"},{"relation":"related","target_id":"sgkb.business-industry.doing-business"},{"relation":"topics","target_id":"sgtopic.business.biomedical-pharma"},{"relation":"entities","target_id":"sg.agency.edb"},{"relation":"entities","target_id":"sg.agency.astar"},{"relation":"entities","target_id":"sg.agency.hsa"}],"locales":{"en":{"markdown":"# Biomedical and Pharma Anchors\n\nUse each row with its as-of date. Manufacturing regulation (HSA) is distinct from clinical healthcare (MOH). Narrative lives in [biomedical and pharma](\/en\/knowledge\/article\/sgkb.business-industry.biomedical-and-pharma).\n\n## Scale and GDP contribution\n\n| Metric | Value | Denominator \/ notes | As of |\n|---|---|---|---|\n| BMS GDP contribution | About 1.9% of GDP | Biopharmaceutical + medical technology activity | 2024 |\n| Product value for global markets | More than S$32 billion | >85% increase vs two decades earlier | 2024 framing |\n| Manufacturing plants | More than 60 | BMS manufacturing plants in Singapore | Accessed Aug 2026 |\n| R&D centres | More than 30 | Corporate\/public research centres | Accessed Aug 2026 |\n| Regional headquarters | More than 80 | Including eight of top 10 biopharma firms (gov framing) | Accessed Aug 2026 |\n\nSource: [EDB biomedical powerhouse](https:\/\/www.edb.gov.sg\/en\/business-insights\/insights\/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html), accessed 9 August 2026.\n\n## Manufacturing cluster share (April 2026)\n\n| Metric | Value | Notes | As of |\n|---|---:|---|---|\n| Biomedical share of manufacturing output | 11.3% | Index basis 2025=100 | Apr 2026 |\n| Pharmaceuticals share | 3.7% | Within manufacturing output index | Apr 2026 |\n| Medical technology share | 7.6% | Within manufacturing output index | Apr 2026 |\n| Biomedical output YoY | \u221216.1% | Softer devices + lower biologics | Apr 2026 |\n\nSource: [EDB Monthly Manufacturing Performance](https:\/\/www.edb.gov.sg\/en\/about-edb\/media-releases-publications\/monthly-manufacturing-performance.html), with the [April 2026 media release](https:\/\/www.edb.gov.sg\/content\/dam\/edb-en\/about-edb\/media-releases\/manufacturing-statistics\/Monthly_Manufacturing_Activities\/Monthly%20Manufacturing%20Performance%20April%202026.pdf), accessed 14 August 2026.\n\n## Investment and campuses\n\n| Anchor | Value | Notes | As of |\n|---|---|---|---|\n| Fixed-asset investments (BMS) | S$4.4 billion | Projected 1,775 jobs over five years | 2025 |\n| Biopolis | Opened Oct 2003 | one-north biomedical R&D campus | 2003 |\n| Tuas Biomedical Park | Manufacturing park (JTC) | Distinct from clinical hospitals | Ongoing |\n\nSource: [MTI PQ reply](https:\/\/www.mti.gov.sg\/newsroom\/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers\/); EDB\/NAS campus framing, accessed 9 August 2026.","summary":"Dated Singapore biomedical manufacturing scale, GDP contribution, plant counts, and Biopolis\/Tuas anchors \u2014 distinct from clinical healthcare financing.","title":"Biomedical and Pharma Anchors"},"zh":{"markdown":"# \u751f\u7269\u533b\u836f\u4e0e\u5236\u836f\u4e1a\u652f\u67f1\n\n\u6bcf\u4e00\u884c\u5747\u5e94\u7ed3\u5408\u5176\u622a\u81f3\u65e5\u671f\u4f7f\u7528\u3002\u5236\u9020\u4e1a\u76d1\u7ba1\uff08HSA\uff09\u4e0e\u4e34\u5e8a\u533b\u7597\uff08MOH\uff09\u4e0d\u540c\u3002\u53d9\u8ff0\u5185\u5bb9\u89c1[\u751f\u7269\u533b\u836f\u4e0e\u5236\u836f\u4e1a](\/zh\/knowledge\/article\/sgkb.business-industry.biomedical-and-pharma)\u3002\n\n## \u89c4\u6a21\u4e0e GDP \u8d21\u732e\n\n| \u6307\u6807 | \u6570\u503c | \u5206\u6bcd \/ \u5907\u6ce8 | \u622a\u81f3 |\n|---|---|---|---|\n| BMS \u5bf9 GDP \u7684\u8d21\u732e | GDP \u7684\u7ea6 1.9% | \u751f\u7269\u5236\u836f + \u533b\u7597\u6280\u672f\u6d3b\u52a8 | 2024 |\n| \u9762\u5411\u5168\u7403\u5e02\u573a\u7684\u4ea7\u54c1\u4ef7\u503c | \u8d85\u8fc7 32 \u5341\u4ebf\u65b0\u5143 | \u8f83\u4e8c\u5341\u5e74\u524d\u589e\u957f >85% | 2024 \u5e74\u53e3\u5f84 |\n| \u5236\u9020\u5de5\u5382 | \u8d85\u8fc7 60 \u4e2a | \u65b0\u52a0\u5761\u7684 BMS \u5236\u9020\u5de5\u5382 | \u622a\u81f3 2026 \u5e74\u516b\u6708\u8bbf\u95ee |\n| \u7814\u53d1\u4e2d\u5fc3 | \u8d85\u8fc7 30 \u4e2a | \u4f01\u4e1a \/ \u516c\u5171\u7814\u7a76\u4e2d\u5fc3 | \u622a\u81f3 2026 \u5e74\u516b\u6708\u8bbf\u95ee |\n| \u533a\u57df\u603b\u90e8 | \u8d85\u8fc7 80 \u4e2a | \u5305\u62ec\u5168\u7403\u524d 10 \u5bb6\u751f\u7269\u5236\u836f\u4f01\u4e1a\u4e2d\u7684\u516b\u5bb6\uff08\u653f\u5e9c\u53e3\u5f84\uff09 | \u622a\u81f3 2026 \u5e74\u516b\u6708\u8bbf\u95ee |\n\n\u6765\u6e90\uff1a[EDB \u751f\u7269\u533b\u836f\u5f3a\u56fd](https:\/\/www.edb.gov.sg\/en\/business-insights\/insights\/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html)\uff0c2026 \u5e74\u516b\u6708 9 \u65e5\u8bbf\u95ee\u3002\n\n## \u5236\u9020\u4e1a\u96c6\u7fa4\u5360\u6bd4\uff082026 \u5e74\u56db\u6708\uff09\n\n| \u6307\u6807 | \u6570\u503c | \u5907\u6ce8 | \u622a\u81f3 |\n|---|---:|---|---|\n| \u751f\u7269\u533b\u836f\u5360\u5236\u9020\u4e1a\u4ea7\u51fa\u7684\u6bd4\u91cd | 11.3% | \u6307\u6570\u57fa\u51c6\u4e3a 2025=100 | 2026 \u5e74\u56db\u6708 |\n| \u5236\u836f\u4e1a\u5360\u6bd4 | 3.7% | \u5360\u5236\u9020\u4e1a\u4ea7\u51fa\u6307\u6570\u7684\u6bd4\u91cd | 2026 \u5e74\u56db\u6708 |\n| \u533b\u7597\u6280\u672f\u5360\u6bd4 | 7.6% | \u5360\u5236\u9020\u4e1a\u4ea7\u51fa\u6307\u6570\u7684\u6bd4\u91cd | 2026 \u5e74\u56db\u6708 |\n| \u751f\u7269\u533b\u836f\u4ea7\u51fa\u540c\u6bd4 | \u221216.1% | \u533b\u7597\u5668\u68b0\u8868\u73b0\u504f\u5f31 + \u751f\u7269\u5236\u5242\u4ea7\u51fa\u4e0b\u964d | 2026 \u5e74\u56db\u6708 |\n\n\u6765\u6e90\uff1a[EDB \u6708\u5ea6\u5236\u9020\u4e1a\u8868\u73b0](https:\/\/www.edb.gov.sg\/en\/about-edb\/media-releases-publications\/monthly-manufacturing-performance.html)\uff0c\u4ee5\u53ca[2026 \u5e74\u56db\u6708\u5a92\u4f53\u516c\u544a](https:\/\/www.edb.gov.sg\/content\/dam\/edb-en\/about-edb\/media-releases\/manufacturing-statistics\/Monthly_Manufacturing_Activities\/Monthly%20Manufacturing%20Performance%20April%202026.pdf)\uff0c2026 \u5e74\u516b\u6708 14 \u65e5\u8bbf\u95ee\u3002\n\n## \u6295\u8d44\u4e0e\u56ed\u533a\n\n| \u652f\u67f1 | \u6570\u503c | \u5907\u6ce8 | \u622a\u81f3 |\n|---|---|---|---|\n| \u56fa\u5b9a\u8d44\u4ea7\u6295\u8d44\uff08BMS\uff09 | 4.4 \u5341\u4ebf\u65b0\u5143 | \u9884\u8ba1\u4e94\u5e74\u5185\u521b\u9020 1,775 \u4e2a\u5c31\u4e1a\u5c97\u4f4d | 2025 |\n| Biopolis | 2003 \u5e74\u5341\u6708\u5f00\u653e | one-north \u751f\u7269\u533b\u836f\u7814\u53d1\u56ed\u533a | 2003 |\n| Tuas Biomedical Park | \u5236\u9020\u4e1a\u56ed\u533a\uff08JTC\uff09 | \u4e0e\u4e34\u5e8a\u533b\u9662\u4e0d\u540c | \u6301\u7eed\u8fd0\u8425 |\n\n\u6765\u6e90\uff1a[MTI \u5bf9\u56fd\u4f1a\u4e66\u9762\u63d0\u95ee\u7684\u7b54\u590d](https:\/\/www.mti.gov.sg\/newsroom\/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers\/)\uff1bEDB \/ NAS \u56ed\u533a\u53e3\u5f84\uff0c2026 \u5e74\u516b\u6708 9 \u65e5\u8bbf\u95ee\u3002","summary":"\u6309\u65e5\u671f\u5217\u51fa\u7684\u65b0\u52a0\u5761\u751f\u7269\u533b\u836f\u5236\u9020\u4e1a\u89c4\u6a21\u3001GDP \u8d21\u732e\u3001\u5de5\u5382\u6570\u91cf\u4ee5\u53ca Biopolis\/Tuas \u652f\u67f1\u6570\u636e\u2014\u2014\u4e0e\u4e34\u5e8a\u533b\u7597\u878d\u8d44\u4e0d\u540c\u3002","title":"\u751f\u7269\u533b\u836f\u4e0e\u5236\u836f\u4e1a\u652f\u67f1"}},"source_id":"sgkb.data.biomedical-pharma-anchors","status":"verified","summary_en":"Dated Singapore biomedical manufacturing scale, GDP contribution, plant counts, and Biopolis\/Tuas anchors \u2014 distinct from clinical healthcare financing.","summary_zh":"\u6309\u65e5\u671f\u5217\u51fa\u7684\u65b0\u52a0\u5761\u751f\u7269\u533b\u836f\u5236\u9020\u4e1a\u89c4\u6a21\u3001GDP \u8d21\u732e\u3001\u5de5\u5382\u6570\u91cf\u4ee5\u53ca Biopolis\/Tuas \u652f\u67f1\u6570\u636e\u2014\u2014\u4e0e\u4e34\u5e8a\u533b\u7597\u878d\u8d44\u4e0d\u540c\u3002","title_en":"Biomedical and Pharma Anchors","title_zh":"\u751f\u7269\u533b\u836f\u4e0e\u5236\u836f\u4e1a\u652f\u67f1"},"search_text":"Biomedical and Pharma Anchors\n\u751f\u7269\u533b\u836f\u4e0e\u5236\u836f\u4e1a\u652f\u67f1\nDated Singapore biomedical manufacturing scale, GDP contribution, plant counts, and Biopolis\/Tuas anchors \u2014 distinct from clinical healthcare financing.\n\u6309\u65e5\u671f\u5217\u51fa\u7684\u65b0\u52a0\u5761\u751f\u7269\u533b\u836f\u5236\u9020\u4e1a\u89c4\u6a21\u3001GDP \u8d21\u732e\u3001\u5de5\u5382\u6570\u91cf\u4ee5\u53ca Biopolis\/Tuas \u652f\u67f1\u6570\u636e\u2014\u2014\u4e0e\u4e34\u5e8a\u533b\u7597\u878d\u8d44\u4e0d\u540c\u3002\n{\"aliases\":[\"BMS manufacturing\",\"Tuas Biomedical Park\",\"Biopolis\"],\"aliases_i18n\":[],\"canonical_format\":\"markdown\",\"classification_confidence\":\"high\",\"classification_source\":\"curated\",\"document_id\":\"sgkb.data.biomedical-pharma-anchors\",\"document_sha256\":\"8f6acb12a339ee33ae4721eb4494198ace56c8d1992f128224d55dad55cf2830\",\"document_type\":\"dataset\",\"domain\":\"data\",\"entities\":[\"sg.agency.edb\",\"sg.agency.astar\",\"sg.agency.hsa\"],\"facets\":[\"business\",\"current\",\"institution\",\"policy\",\"statistics\"],\"geographic_scope\":[\"national\"],\"grain\":\"one dated BMS GDP\\\/plant\\\/VA or campus investment anchor\",\"id\":\"sgkb.data.biomedical-pharma-anchors\",\"jurisdiction\":\"SG\",\"language\":\"en\",\"last_verified\":\"2026-08-09\",\"path\":\"data\\\/biomedical-pharma-anchors.md\",\"related\":[\"biomedical-and-pharma\",\"astar-and-public-research\",\"doing-business\"],\"sources\":[{\"accessed\":\"2026-08-09\",\"publisher\":\"Economic Development Board\",\"tier\":1,\"title\":\"EDB \u2014 Singapore's rise as a biomedical sciences powerhouse\",\"url\":\"https:\\\/\\\/www.edb.gov.sg\\\/en\\\/business-insights\\\/insights\\\/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html\"},{\"accessed\":\"2026-08-09\",\"publisher\":\"Economic Development Board\",\"tier\":1,\"title\":\"EDB \u2014 Monthly Manufacturing Performance\",\"url\":\"https:\\\/\\\/www.edb.gov.sg\\\/en\\\/about-edb\\\/media-releases-publications\\\/monthly-manufacturing-performance.html\"},{\"accessed\":\"2026-08-14\",\"published\":\"2026-05-26\",\"publisher\":\"Economic Development Board\",\"tier\":1,\"title\":\"EDB \u2014 Monthly Manufacturing Performance April 2026 infographic\",\"url\":\"https:\\\/\\\/www.edb.gov.sg\\\/content\\\/dam\\\/edb-en\\\/about-edb\\\/media-releases\\\/manufacturing-statistics\\\/Monthly_Manufacturing_Activities\\\/Monthly%20Manufacturing%20Performance%20April%202026.pdf\"},{\"accessed\":\"2026-08-09\",\"publisher\":\"Ministry of Trade and Industry\",\"tier\":1,\"title\":\"MTI \u2014 Written reply on biomedical sector resilience\",\"url\":\"https:\\\/\\\/www.mti.gov.sg\\\/newsroom\\\/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers\\\/\"}],\"status\":\"verified\",\"summary\":\"Dated Singapore biomedical manufacturing scale, GDP contribution, plant counts, and Biopolis\\\/Tuas anchors \u2014 distinct from clinical healthcare financing.\",\"tags\":[\"manufacturing\",\"statistics\",\"policy\",\"investment\"],\"temporal_scope\":\"current\",\"title\":\"Biomedical and Pharma Anchors\",\"topics\":[\"sgtopic.business.biomedical-pharma\"],\"update_cadence\":\"after EDB manufacturing stats or BMS investment announcements\",\"volatility\":\"fast\"}\n# Biomedical and Pharma Anchors\n\nUse each row with its as-of date. Manufacturing regulation (HSA) is distinct from clinical healthcare (MOH). Narrative lives in [biomedical and pharma](\/en\/knowledge\/article\/sgkb.business-industry.biomedical-and-pharma).\n\n## Scale and GDP contribution\n\n| Metric | Value | Denominator \/ notes | As of |\n|---|---|---|---|\n| BMS GDP contribution | About 1.9% of GDP | Biopharmaceutical + medical technology activity | 2024 |\n| Product value for global markets | More than S$32 billion | >85% increase vs two decades earlier | 2024 framing |\n| Manufacturing plants | More than 60 | BMS manufacturing plants in Singapore | Accessed Aug 2026 |\n| R&D centres | More than 30 | Corporate\/public research centres | Accessed Aug 2026 |\n| Regional headquarters | More than 80 | Including eight of top 10 biopharma firms (gov framing) | Accessed Aug 2026 |\n\nSource: [EDB biomedical powerhouse](https:\/\/www.edb.gov.sg\/en\/business-insights\/insights\/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html), accessed 9 August 2026.\n\n## Manufacturing cluster share (April 2026)\n\n| Metric | Value | Notes | As of |\n|---|---:|---|---|\n| Biomedical share of manufacturing output | 11.3% | Index basis 2025=100 | Apr 2026 |\n| Pharmaceuticals share | 3.7% | Within manufacturing output index | Apr 2026 |\n| Medical technology share | 7.6% | Within manufacturing output index | Apr 2026 |\n| Biomedical output YoY | \u221216.1% | Softer devices + lower biologics | Apr 2026 |\n\nSource: [EDB Monthly Manufacturing Performance](https:\/\/www.edb.gov.sg\/en\/about-edb\/media-releases-publications\/monthly-manufacturing-performance.html), with the [April 2026 media release](https:\/\/www.edb.gov.sg\/content\/dam\/edb-en\/about-edb\/media-releases\/manufacturing-statistics\/Monthly_Manufacturing_Activities\/Monthly%20Manufacturing%20Performance%20April%202026.pdf), accessed 14 August 2026.\n\n## Investment and campuses\n\n| Anchor | Value | Notes | As of |\n|---|---|---|---|\n| Fixed-asset investments (BMS) | S$4.4 billion | Projected 1,775 jobs over five years | 2025 |\n| Biopolis | Opened Oct 2003 | one-north biomedical R&D campus | 2003 |\n| Tuas Biomedical Park | Manufacturing park (JTC) | Distinct from clinical hospitals | Ongoing |\n\nSource: [MTI PQ reply](https:\/\/www.mti.gov.sg\/newsroom\/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers\/); EDB\/NAS campus framing, accessed 9 August 2026.\n# \u751f\u7269\u533b\u836f\u4e0e\u5236\u836f\u4e1a\u652f\u67f1\n\n\u6bcf\u4e00\u884c\u5747\u5e94\u7ed3\u5408\u5176\u622a\u81f3\u65e5\u671f\u4f7f\u7528\u3002\u5236\u9020\u4e1a\u76d1\u7ba1\uff08HSA\uff09\u4e0e\u4e34\u5e8a\u533b\u7597\uff08MOH\uff09\u4e0d\u540c\u3002\u53d9\u8ff0\u5185\u5bb9\u89c1[\u751f\u7269\u533b\u836f\u4e0e\u5236\u836f\u4e1a](\/zh\/knowledge\/article\/sgkb.business-industry.biomedical-and-pharma)\u3002\n\n## \u89c4\u6a21\u4e0e GDP \u8d21\u732e\n\n| \u6307\u6807 | \u6570\u503c | \u5206\u6bcd \/ \u5907\u6ce8 | \u622a\u81f3 |\n|---|---|---|---|\n| BMS \u5bf9 GDP \u7684\u8d21\u732e | GDP \u7684\u7ea6 1.9% | \u751f\u7269\u5236\u836f + \u533b\u7597\u6280\u672f\u6d3b\u52a8 | 2024 |\n| \u9762\u5411\u5168\u7403\u5e02\u573a\u7684\u4ea7\u54c1\u4ef7\u503c | \u8d85\u8fc7 32 \u5341\u4ebf\u65b0\u5143 | \u8f83\u4e8c\u5341\u5e74\u524d\u589e\u957f >85% | 2024 \u5e74\u53e3\u5f84 |\n| \u5236\u9020\u5de5\u5382 | \u8d85\u8fc7 60 \u4e2a | \u65b0\u52a0\u5761\u7684 BMS \u5236\u9020\u5de5\u5382 | \u622a\u81f3 2026 \u5e74\u516b\u6708\u8bbf\u95ee |\n| \u7814\u53d1\u4e2d\u5fc3 | \u8d85\u8fc7 30 \u4e2a | \u4f01\u4e1a \/ \u516c\u5171\u7814\u7a76\u4e2d\u5fc3 | \u622a\u81f3 2026 \u5e74\u516b\u6708\u8bbf\u95ee |\n| \u533a\u57df\u603b\u90e8 | \u8d85\u8fc7 80 \u4e2a | \u5305\u62ec\u5168\u7403\u524d 10 \u5bb6\u751f\u7269\u5236\u836f\u4f01\u4e1a\u4e2d\u7684\u516b\u5bb6\uff08\u653f\u5e9c\u53e3\u5f84\uff09 | \u622a\u81f3 2026 \u5e74\u516b\u6708\u8bbf\u95ee |\n\n\u6765\u6e90\uff1a[EDB \u751f\u7269\u533b\u836f\u5f3a\u56fd](https:\/\/www.edb.gov.sg\/en\/business-insights\/insights\/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html)\uff0c2026 \u5e74\u516b\u6708 9 \u65e5\u8bbf\u95ee\u3002\n\n## \u5236\u9020\u4e1a\u96c6\u7fa4\u5360\u6bd4\uff082026 \u5e74\u56db\u6708\uff09\n\n| \u6307\u6807 | \u6570\u503c | \u5907\u6ce8 | \u622a\u81f3 |\n|---|---:|---|---|\n| \u751f\u7269\u533b\u836f\u5360\u5236\u9020\u4e1a\u4ea7\u51fa\u7684\u6bd4\u91cd | 11.3% | \u6307\u6570\u57fa\u51c6\u4e3a 2025=100 | 2026 \u5e74\u56db\u6708 |\n| \u5236\u836f\u4e1a\u5360\u6bd4 | 3.7% | \u5360\u5236\u9020\u4e1a\u4ea7\u51fa\u6307\u6570\u7684\u6bd4\u91cd | 2026 \u5e74\u56db\u6708 |\n| \u533b\u7597\u6280\u672f\u5360\u6bd4 | 7.6% | \u5360\u5236\u9020\u4e1a\u4ea7\u51fa\u6307\u6570\u7684\u6bd4\u91cd | 2026 \u5e74\u56db\u6708 |\n| \u751f\u7269\u533b\u836f\u4ea7\u51fa\u540c\u6bd4 | \u221216.1% | \u533b\u7597\u5668\u68b0\u8868\u73b0\u504f\u5f31 + \u751f\u7269\u5236\u5242\u4ea7\u51fa\u4e0b\u964d | 2026 \u5e74\u56db\u6708 |\n\n\u6765\u6e90\uff1a[EDB \u6708\u5ea6\u5236\u9020\u4e1a\u8868\u73b0](https:\/\/www.edb.gov.sg\/en\/about-edb\/media-releases-publications\/monthly-manufacturing-performance.html)\uff0c\u4ee5\u53ca[2026 \u5e74\u56db\u6708\u5a92\u4f53\u516c\u544a](https:\/\/www.edb.gov.sg\/content\/dam\/edb-en\/about-edb\/media-releases\/manufacturing-statistics\/Monthly_Manufacturing_Activities\/Monthly%20Manufacturing%20Performance%20April%202026.pdf)\uff0c2026 \u5e74\u516b\u6708 14 \u65e5\u8bbf\u95ee\u3002\n\n## \u6295\u8d44\u4e0e\u56ed\u533a\n\n| \u652f\u67f1 | \u6570\u503c | \u5907\u6ce8 | \u622a\u81f3 |\n|---|---|---|---|\n| \u56fa\u5b9a\u8d44\u4ea7\u6295\u8d44\uff08BMS\uff09 | 4.4 \u5341\u4ebf\u65b0\u5143 | \u9884\u8ba1\u4e94\u5e74\u5185\u521b\u9020 1,775 \u4e2a\u5c31\u4e1a\u5c97\u4f4d | 2025 |\n| Biopolis | 2003 \u5e74\u5341\u6708\u5f00\u653e | one-north \u751f\u7269\u533b\u836f\u7814\u53d1\u56ed\u533a | 2003 |\n| Tuas Biomedical Park | \u5236\u9020\u4e1a\u56ed\u533a\uff08JTC\uff09 | \u4e0e\u4e34\u5e8a\u533b\u9662\u4e0d\u540c | \u6301\u7eed\u8fd0\u8425 |\n\n\u6765\u6e90\uff1a[MTI \u5bf9\u56fd\u4f1a\u4e66\u9762\u63d0\u95ee\u7684\u7b54\u590d](https:\/\/www.mti.gov.sg\/newsroom\/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers\/)\uff1bEDB \/ NAS \u56ed\u533a\u53e3\u5f84\uff0c2026 \u5e74\u516b\u6708 9 \u65e5\u8bbf\u95ee\u3002"},"related":[{"id":90716,"source_id":"sgkb.science-research.astar-and-public-research","kind":"article","title_en":"A*STAR and Public Research Institutes","title_zh":"A*STAR \u4e0e\u516c\u5171\u7814\u7a76\u673a\u6784","assurance":null,"subtype":null},{"id":89655,"source_id":"sgkb.business-industry.biomedical-and-pharma","kind":"article","title_en":"Biomedical and Pharma","title_zh":"\u751f\u7269\u533b\u5b66\u4e0e\u5236\u836f","assurance":null,"subtype":null},{"id":89685,"source_id":"sgkb.business-industry.doing-business","kind":"article","title_en":"Doing Business in Singapore","title_zh":"\u5728\u65b0\u52a0\u5761\u7ecf\u8425\u4e1a\u52a1","assurance":null,"subtype":null},{"id":79781,"source_id":"sg.agency.astar","kind":"entity","title_en":"Agency for Science, Technology and Research","title_zh":"\u65b0\u52a0\u5761\u79d1\u6280\u7814\u7a76\u5c40","assurance":null,"subtype":"statutory-board"},{"id":79809,"source_id":"sg.agency.hsa","kind":"entity","title_en":"Health Sciences Authority","title_zh":"\u536b\u751f\u79d1\u5b66\u5c40","assurance":null,"subtype":"statutory-board"},{"id":79800,"source_id":"sg.agency.edb","kind":"entity","title_en":"Singapore Economic Development Board","title_zh":"\u65b0\u52a0\u5761\u7ecf\u6d4e\u53d1\u5c55\u5c40","assurance":null,"subtype":"agency"},{"id":91949,"source_id":"sgtopic.business.biomedical-pharma","kind":"topic","title_en":"Biomedical and pharmaceuticals","title_zh":"\u751f\u7269\u533b\u5b66\u4e0e\u5236\u836f\u4e1a","assurance":null,"subtype":null}]}